Kenvue (NYSE:KVUE - Get Free Report) had its price target reduced by equities research analysts at Barclays from $23.00 to $22.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Barclays's target price would indicate a potential upside of 0.71% from the stock's current price.
KVUE has been the subject of a number of other reports. Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. Bank of America decreased their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday. Evercore ISI started coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Finally, UBS Group increased their price objective on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Kenvue presently has a consensus rating of "Hold" and an average target price of $24.88.
Read Our Latest Stock Analysis on KVUE
Kenvue Stock Performance
Shares of NYSE KVUE traded up $0.46 during trading hours on Tuesday, reaching $21.85. The stock had a trading volume of 21,829,077 shares, compared to its average volume of 16,333,023. The firm has a market cap of $41.91 billion, a price-to-earnings ratio of 39.72, a PEG ratio of 3.33 and a beta of 0.83. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue has a fifty-two week low of $17.85 and a fifty-two week high of $25.17. The firm has a 50-day moving average of $22.24 and a 200-day moving average of $22.29.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period in the prior year, the business earned $0.28 EPS. The firm's revenue was down 3.9% compared to the same quarter last year. Equities research analysts predict that Kenvue will post 1.14 earnings per share for the current year.
Institutional Trading of Kenvue
Hedge funds have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after buying an additional 4,034 shares during the period. Starboard Value LP purchased a new position in Kenvue in the 4th quarter valued at approximately $467,864,000. TrueMark Investments LLC increased its stake in Kenvue by 9.3% in the 4th quarter. TrueMark Investments LLC now owns 190,595 shares of the company's stock valued at $4,069,000 after purchasing an additional 16,161 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new position in Kenvue in the 1st quarter valued at approximately $413,000. Finally, DLK Investment Management LLC purchased a new position in Kenvue in the 1st quarter valued at approximately $4,100,000. 97.64% of the stock is owned by institutional investors and hedge funds.
Kenvue Company Profile
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
